Abstract
Background:
Elevated levels of inflammatory biomarkers and brain natriuretic peptide (BNP) are associated with increased mortality in patients with heart failure (HF).
Hypothesis:
The aim of the current study was to assess the correlation between circulating biomarkers and ventricular tachyarrhythmias among patients with HF.
Methods:
Blood samples from 50 stable ambulatory HF patients with moderate to severe systolic left ventricular (LV) dysfunction and an implantable cardioverter defibrillator (ICD) were analyzed for interleukin 6 (IL‐6), tumor necrosis factor‐alpha (TNF‐α), high‐sensitivity C‐reactive protein (hsCRP) and BNP. Thereafter, the patients were followed for a mean period of 152 ± 44 days, during which ventricular tachyarrhythmias were recorded by the ICDs.
Results:
Follow‐up data were obtained from 47 patients. Of them, 45 (96%) had ischemic cardiomyopathy, 38 (81%) had New York Heart Association class I–II, 43 (91%) were males, and the mean age was 68.6 ± 11.1 years. During follow‐up, 5 patients (11%) had nonsustained ventricular tachycardia (NSVT), 6 patients (13%) had sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and 36 patients (76%) had no events. The circulating biomarkers' levels upon enrollment were not significantly different between patients who subsequently had NSVT or VT/VF and patients who were free of events.
Conclusions:
No correlation was found between plasma levels of IL‐6, TNF‐α, hsCRP and BNP and ventricular arrhythmic events among stable HF patients during an intermediate term follow‐up of 5.1 months. Further studies are still required to assess the association between these biomarkers and long‐term risk of ventricular tachyarrhythmia. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: heart failure, inflammatory biomarkers, BNP, ventricular tachyarrhythmias
Full Text
The Full Text of this article is available as a PDF (241.0 KB).
References
- 1. Aukrust P, Damas JK, Gullestad L: Immunomodulating therapy: new treatment modality in congestive heart failure Review. Congest Heart Fail 2003; 9: 64–69. [DOI] [PubMed] [Google Scholar]
- 2. Paulus WJ: Cytokines and heart failure Review. Heart Fail Monit 2000; 1: 50–56. [PubMed] [Google Scholar]
- 3. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future Review. Circ Res 2002; 91: 988–998. [DOI] [PubMed] [Google Scholar]
- 4. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, et al.: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060–3067. [DOI] [PubMed] [Google Scholar]
- 5. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, et al.: Interleukin‐6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin‐6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 391–398. [DOI] [PubMed] [Google Scholar]
- 6. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, et al.: High levels of plasma brain natriuretic peptide and interleukin‐6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587–1593. [DOI] [PubMed] [Google Scholar]
- 7. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, et al.: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001; 103: 2055–9. [DOI] [PubMed] [Google Scholar]
- 8. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, et al.: Independent prognostic value of elevated high‐sensitivity C‐reactive protein in chronic heart failure. Am Heart J 2004; 147: 931–938. [DOI] [PubMed] [Google Scholar]
- 9. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, et al.: C‐reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428–1434. [DOI] [PubMed] [Google Scholar]
- 10. Alonzo‐Martinez JL, Llorente‐Diez B, Echegaray Agara M, Olaz‐Preciado F, Urbieta‐Echezarreta M, et al.: C‐reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4: 331–336. [DOI] [PubMed] [Google Scholar]
- 11. Doust JA, Pietrzak E, Dobson A, Glasziou PP: How well does B‐type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005; 330: 625–633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, et al.: B‐type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397. [DOI] [PubMed] [Google Scholar]
- 13. Watanabe J, Shiba N, Shinozaki T, Koseki Y, Karibe A, et al.: Prognostic value of plasma natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail 2005; 11: 50–55. [DOI] [PubMed] [Google Scholar]
- 14. Al‐Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, et al.: Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149: 1020–1034. [DOI] [PubMed] [Google Scholar]
- 15. Oseroff O, Retyk E, Bochoeyer A: Subanalyses of secondary prevention implantable cardioverter‐defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004; 19: 26–30. [DOI] [PubMed] [Google Scholar]
- 16. Eckardt L, Haverkamp W, Johna R, Bocker D, Deng MC, et al.: Arrhythmias in heart failure: current concepts of mechanisms and therapy. J Cardiovasc Electrophysiol 2000; 11: 106–117. [DOI] [PubMed] [Google Scholar]
- 17. Torre‐Amione G, Kapadia S, Benedict C, Oral H, Young JB, et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201–1206. [DOI] [PubMed] [Google Scholar]
- 18. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, et al.: Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 2002; 23: 70–78. [DOI] [PubMed] [Google Scholar]
- 19. Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, et al.: Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4: 1017–1022. [DOI] [PubMed] [Google Scholar]
- 20. Rodriguez‐Reyna TS, Arrieta O, Castillo‐Martinez L, Orea‐Tejeda A, Guevara P, et al.: Tumor necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure. Clin Invest Med 2005; 28: 23–29. [PubMed] [Google Scholar]
- 21. Chirinos JA, Zambrano JP, Chakko S, Schob A, Veerani A, et al.: Usefulness of C‐reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005; 95: 88–90. [DOI] [PubMed] [Google Scholar]
- 22. Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, et al.: High‐sensitivity C‐reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26: 2245–2250. [DOI] [PubMed] [Google Scholar]
- 23. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, et al.: Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005; 165: 1304–1309. [DOI] [PubMed] [Google Scholar]
- 24. Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, et al.: Amino‐terminal pro‐brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter‐defibrillators. Chest 2006; 128: 2604–2610. [DOI] [PubMed] [Google Scholar]
- 25. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, et al.: Preimplantation B‐type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190–195. [DOI] [PMC free article] [PubMed] [Google Scholar]